Overview

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
Phase:
Phase 2
Details
Lead Sponsor:
Naurex, Inc
Naurex, Inc, an affiliate of Allergan plc